Systemic Autoimmune Diseases with Neurological Manifestations

  • Richard Choi
  • Valarie Gendron
  • Mac McLaughlin
  • Jonathan Cahill
  • Fathima Qadeer
  • Syed A. Rizvi
Part of the Current Clinical Neurology book series (CCNEU)


In this chapter, we discuss several systemic diseases that have an immune-mediated pathogenesis. Although most of these diseases are infrequent and seldom affect the neurological system, clinicians should always remain cognizant of their existence. Even though a detailed encounter with each of the following diseases is out of the scope of this chapter, we cover the most commonly encountered and the most prominent neurological and clinical manifestations to help guide the clinician into identifying, diagnosing, and treating these illnesses.


Immune mediated Multifactorial Antibodies Remissions Anticoagulation Granuloma 


  1. 1.
    Rahman A, Iseberg DA. Mechanisms of disease: systemic lupus erythematosus. N Engl J Med. 2008;358:929–39.PubMedCrossRefGoogle Scholar
  2. 2.
    Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.PubMedCrossRefGoogle Scholar
  3. 3.
    James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997;100:3019–26.PubMedCrossRefGoogle Scholar
  4. 4.
    Isenberg DA, Shoenfeld Y, Walport M, et al. Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum. 1985;28:999–1007.PubMedCrossRefGoogle Scholar
  5. 5.
    Walport M. Complement and systemic lupus erythematosus. Arthritis Res. 2002;4 Suppl 3:S279–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus. 1995;3:393–5.CrossRefGoogle Scholar
  7. 7.
    Hanly JG, Hong C, Smith S, et al. A prospective analysis of cognitive function and anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:728–34.PubMedCrossRefGoogle Scholar
  8. 8.
    Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:735–41.PubMedCrossRefGoogle Scholar
  9. 9.
    Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol. 2005;12:392–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Harrison M, Ravdin L, Volpe B, et al. Anti-NR2 antibody does not identify cognitive impairment in a general SLE population. Arthritis Rheum. 2004;50:S596.Google Scholar
  11. 11.
    Hanly JG. Neuropsychiatric lupus. Curr Rheumatol Rep. 2001;3:205–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum. 1996;39:9–22.PubMedCrossRefGoogle Scholar
  13. 13.
    Hanly JG, Walsh NN, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19:732–41.PubMedGoogle Scholar
  14. 14.
    Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin. 2009;28:61–73.CrossRefGoogle Scholar
  15. 15.
    Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56:265–73.PubMedCrossRefGoogle Scholar
  16. 16.
    Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol. 1996;25:191–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Yoshio T, Hirata D, Onda K, et al. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol. 2005;32:34–9.PubMedGoogle Scholar
  18. 18.
    Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Greenberg BM, Thomas KP, Krishnan C, et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange or cyclophosphamide. Neurology. 2007;68:1614–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Ferreira S, D’Cruz DP, Hughes GR. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology (Oxford). 2005;68:434–42.CrossRefGoogle Scholar
  21. 21.
    Mitsikostas DD, Sfikakis PP, Goadsby PJ. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain. 2004;127:1200–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57:496–500.PubMedGoogle Scholar
  23. 23.
    Borchers AT, Aoki CA, Naguwa SM, et al. Neuropsychiatric features of systemic lupus erythematosus. Autoimmun Rev. 2005;4:329–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Petri M, Brodsky R. High-dose cyclophosphamide and stem cell transplantation for refractory systemic lupus erythematosus. JAMA. 2006;295:559–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Crowther MA, Ginsberg JS, Julian J, et al. A Comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Newman LS, Rose CS, Meier LA. Sarcoidosis. N Engl J Med. 1997;336:1224–34.PubMedCrossRefGoogle Scholar
  27. 27.
    Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry. 2009;80:297–304.PubMedCrossRefGoogle Scholar
  28. 28.
    Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol. 2007;7:234–44.PubMedCrossRefGoogle Scholar
  29. 29.
    Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol. 2001;248:363–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Delaney P. Neurologic manifestations in sarcoidosis: review of the literature with a report of 23 cases. Ann Int Med. 1977;87:336–45.PubMedGoogle Scholar
  31. 31.
    Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest. 1997;112:220–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Zajicek JP, Scolding SN, Foster O, et al. Central nervous system sarcoidosis – ­diagnosis and management. Q J Med. 1999;92:103–17.Google Scholar
  33. 33.
    Delande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: A study of 82 patients. Medicine. 2004;83(5):336–45.Google Scholar
  34. 34.
    Govini M, Padovan M, Rizzo N, Trotta F. CNS involvement in primary Sjogren’s syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs. 2001;15(8):597–607.CrossRefGoogle Scholar
  35. 35.
    Mellgren SI, Conn DL, Stevens JC, Dyck PJ. Peripheral neuropathy in primary Sjogren’s syndrome. Neurology. 1989;39:390–4.PubMedGoogle Scholar
  36. 36.
    Chai J, Herrmann D, Stanton M, Barbano RL, Logigian EL. Painful small-fiber neuropathy in Sjogren syndrome. Neurology. 2005;65:925–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Reske D, Petereit HF, Heiss WD. Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system – value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol. 2005;112:207–13.CrossRefGoogle Scholar
  38. 38.
    Behçet H. Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochr. 1937;105:1152–7.Google Scholar
  39. 39.
    Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro-Behçet disease – a review. Neurologist. 2005;11:80–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Al-Araji A, Kidd DP. Neuro-Behçet’s disease: epidemiology, clinical characteristics and management. Lancet Neurol. 2009;8:192–204.PubMedCrossRefGoogle Scholar
  41. 41.
    Akman-Demir G, Serdaroglu P, Tasci B, the Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. Brain. 1999;170:105–11.Google Scholar
  42. 42.
    Borhani Haghighi A, Sharifzad HR, Matin S, Rezaee S. The pathological presentations of Neuro-Behçet’s disease: a case report and review of the literature. Neurologist. 2007;13:209–14.PubMedCrossRefGoogle Scholar
  43. 43.
    Houman MH, Neffati H, Braham A, et al. Behçet’s disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol. 2007;25:S58–64.PubMedGoogle Scholar
  44. 44.
    Ashjazadeh N, Borhani Haghighi A, Samangooei Sh, et al. Neuro-Behçet’s Disease: a masquerader of multiple sclerosis. Exp Mol Pathol. 2003;73:17–22.CrossRefGoogle Scholar
  45. 45.
    Shakir RA, Sulaiman K, Lahn RA, et al. Neurological presentation of neuro-Behçet syndrome: clinical categories. Eur J Neurol. 1990;30:249–53.CrossRefGoogle Scholar
  46. 46.
    Wechesler B, Vidailhet M, Piette JC, et al. Cerebral venous thrombosis in Behçet’s disease: clinical study and long-term follow-up of 25 cases. Neurology. 1992;42:614–8.Google Scholar
  47. 47.
    Worthmann F, Bruns J, Turker T, et al. Muscular involvement in Behçet’s disease: case report and review of the literature. Neuromuscul Disord. 1996;6:247–53.PubMedCrossRefGoogle Scholar
  48. 48.
    International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet disease. Lancet. 1990;335:1078–80.Google Scholar
  49. 49.
    Yazici H, Basaran G, Hamuryudan V, et al. The ten-year mortality in Behçet’s syndrome a report of 24 cases. Br J Rheumatol. 1996;35:139–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Kawai M, Hirohata S. Cerebrospinal fluid beta-2 microglobulin in neuro-Behçet’s syndrome. Folia Psychiatr Neurol Jpn. 1984;38:65–79.Google Scholar
  51. 51.
    Saruhan-Direskeneli G, Yentür SP, Akman-Demir G, Isik N, Serdaroglu P. Cytokines and chemokines in neuro-Behçet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol. 2003;145:127–34.PubMedCrossRefGoogle Scholar
  52. 52.
    Sharief MB, Hentges R, Thomas E. Significance of CSF immunoglobulins in ­monitoring neurologic disease activity in Behçet’s disease. Neurology. 1991;41:1398–401.PubMedGoogle Scholar
  53. 53.
    Jongen PJ, Daelmans HE, Bruneel B, et al. Humoral and cellular immunologic study of cerebrospinal fluid in a patient with Behçet encephalitis. Arch Neurol. 1992;49:1075–8.PubMedGoogle Scholar
  54. 54.
    Kao CH, Lan JL, ChangLai SP, et al. Technetium-99m-HMPAO SPECT and MRI of brain in patients with neuro-Behçet’s syndrome. J Nucl Med. 1998;39:1707–10.PubMedGoogle Scholar
  55. 55.
    Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet’s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2008;67:1656–62.PubMedCrossRefGoogle Scholar
  56. 56.
    Borhani Haghighi A, Safari A. Proposing an algorithm for treatment of different manifestations of neuro-Behçet’s disease. Clin Rheumatol. 2010;29:683–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Bank I, Weart C. Dural sinus thrombosis in Behçet’s disease. Arthritis Rheum. 1984;27:816–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Anderson M. Neurology of Whipple’s disease. J Neurol Neurosurg Psychiatry. 2000;68:2–5.PubMedCrossRefGoogle Scholar
  59. 59.
    Lugassy MM, Louis ED. Neurologic manifestations of Whipple’s disease. Curr Infect Dis Rep. 2006;8:301–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Louis ED, Lynch T, Kauffman P, Fahn S, Odel J. Diagnostic guidelines in central nervous system Whipple’s disease. Ann Neurol. 1996;40:561–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Burk K, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M, et al. Neurological symptoms in patients with biopsy proven celiac disease. Mov Disord. 2009;24:2358–62.PubMedCrossRefGoogle Scholar
  62. 62.
    Fasano A. Where have all the American celiacs gone? Acta Paediatr Suppl. 1996;412:20–4.PubMedCrossRefGoogle Scholar
  63. 63.
    Rampertab SD, Pooran N, Brar P, Singh P, Green PH. Trends in the presentation of celiac disease. Am J Med. 2006;119:355.PubMedCrossRefGoogle Scholar
  64. 64.
    Bushara KO. Neurologic presentation of celiac disease. Gastroenterology. 2005;128:S92–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Richard Choi
    • 1
  • Valarie Gendron
    • 1
  • Mac McLaughlin
    • 2
  • Jonathan Cahill
    • 2
  • Fathima Qadeer
    • 3
  • Syed A. Rizvi
    • 4
  1. 1.Department of NeurologyRhode Island HospitalProvidenceUSA
  2. 2.UMASS Medical SchoolWorcesterUSA
  3. 3.Rhode Island HospitalProvidenceUSA
  4. 4.Department of Clinical NeuroscienceBrown UniversityProvidenceUSA

Personalised recommendations